Clinical Trial Update: Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial of pegylated liposomal doxorubicin (Doxil) with rituximab for relapsed AIDS-related non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids-related Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Effusion Lymphoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Rituximab (rituximab)

Snippet

Sponsor: University of Southern California | Conditions: Non-Hodgkin's Lymphoma, Burkitt Lymphoma | Phase 2 | Status: TERMINATED